Glaxis Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Glaxis Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-20,000	Closed	-$1.06M	–	30
2013 Q4	$1.06M	Buy	+20,000	New	+$1.02M	2.29%	16
2013 Q3	–	Sell	-17,000	Closed	-$759K	–	44
2013 Q2	$759K	Buy	+17,000	New	+$738K	1.79%	21

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glaxis Capital Management's BMY Position: Q1 2014 in Review

Glaxis Capital Management sold out of Bristol-Myers Squibb (BMY) in Q1 2014, closing a stake of 20,000 shares — an estimated $1.06M sold.

Glaxis Capital Management first reported a position in BMY in Q2 2013 and held it in 2 quarters. The position peaked at $1.06M in Q4 2013. 1,327 funds tracked by Wall St. Rank hold BMY as of Q1 2014.

Glaxis Capital Management reported no remaining Bristol-Myers Squibb position as of Q1 2014 after selling out during the quarter.
Glaxis Capital Management sold 20,000 Bristol-Myers Squibb shares in Q1 2014, an estimated $1.06M.
Glaxis Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 2 quarters.
Glaxis Capital Management's Bristol-Myers Squibb position peaked at $1.06M in Q4 2013.
1,327 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2014.

Based on Glaxis Capital Management's 13F filing for Q1 2014, filed 24 Apr 2014.